Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antisense
Biotech
Ionis rare disease candidate ekes out phase 3 win
Out of 54 patients with Alexander disease, those given zilganersen could walk an average of 33.3% faster in a 10-meter walk test at 61 weeks.
Darren Incorvaia
Sep 22, 2025 10:46am
Ono pays $280M upfront for Ionis' phase 2 blood cancer med
Mar 12, 2025 6:30am
Oligonucleotide stops gene expansion driving Huntington's: study
Feb 12, 2025 2:00pm
Sanofi inks $400M biobucks deal for Alloy's antisense platform
Jan 8, 2025 5:08am
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks
Oct 24, 2024 8:55am
Takeda axes Huntington’s pact, freeing Wave to pursue partners
Oct 16, 2024 8:07am